Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) EBITDA: 2014-2020

Historic EBITDA for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to -$3.6 million.

  • Larimar Therapeutics' EBITDA rose 72.46% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.67%. This contributed to the annual value of -$45.3 million for FY2019, which is 26.09% up from last year.
  • Latest data reveals that Larimar Therapeutics reported EBITDA of -$3.6 million as of Q1 2020, which was up 50.37% from -$7.3 million recorded in Q4 2019.
  • In the past 5 years, Larimar Therapeutics' EBITDA registered a high of -$3.6 million during Q1 2020, and its lowest value of -$17.5 million during Q1 2016.
  • In the last 3 years, Larimar Therapeutics' EBITDA had a median value of -$13.1 million in 2019 and averaged -$12.3 million.
  • As far as peak fluctuations go, Larimar Therapeutics' EBITDA tumbled by 30.07% in 2016, and later skyrocketed by 72.46% in 2020.
  • Over the past 5 years, Larimar Therapeutics' EBITDA (Quarterly) stood at -$10.5 million in 2016, then declined by 25.47% to -$13.1 million in 2017, then dropped by 11.13% to -$14.6 million in 2018, then spiked by 50.21% to -$7.3 million in 2019, then skyrocketed by 72.46% to -$3.6 million in 2020.
  • Its EBITDA was -$3.6 million in Q1 2020, compared to -$7.3 million in Q4 2019 and -$12.9 million in Q3 2019.